EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Multizentrische StudieOpen Access · CC BY 4.0

Anti‐ KIT Barzolvolimab for Chronic Spontaneous Urticaria

Marcus Maurer iD, Martin Metz iD, John Anderson, Neetu Talreja, Diane Young, Elizabeth Crowley, Margo Heath-Chiozzi, Rick Ma, Elsa Paradise, Thomas Hawthorne, Diego Alvarado, Jonathan A Bernstein iD

Allergy · 2025-08 · 80 (8) · 2178-2186

DOI: 10.1111/all.16598 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Allergy, online erschienen am 26.05.2025. Verfasst von Marcus Maurer und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Allergology, Charité-Universitätsmedizin Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Chronic Urticaria, Proto-Oncogene Proteins c-kit, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Celldex Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic spontaneous urticaria (CSU) is characterized by mast cell (MC)‐mediated wheals and/or angioedema without identifiable triggers and is driven by MC activation. Barzolvolimab—a monoclonal anti‐KIT antibody—depletes MCs by inhibiting activation of KIT by stem cell factor. We evaluated multiple ascending doses in patients with CSU.

Methods

Phase 1b double‐blind placebo‐controlled trial (NCT04538794) in adults with moderate‐to‐severe (urticaria activity score over 7 days [UAS7] ≥ 16) antihistamine–refractory CSU treated with intravenous barzolvolimab for 12 weeks with a 12‐week follow‐up in four sequentially enrolled cohorts (randomized 4:1 barzolvolimab:placebo): 0.5 mg/kg, Q4W ( n = 9); 1.5 mg/kg, Q4W ( n = 8); 3 mg/kg, Q8W ( n = 9); and 4.5 mg/kg, Q8W ( n = 9). Primary and secondary objectives were safety and disease activity (UAS7 and urticaria control test [UCT]). Pharmacokinetics and pharmacodynamics were assessed.

Results

Patients had high mean (range) baseline CSU activity, with UAS7 = 29.6 (16.3–42.0) for barzolvolimab‐treated, UAS7 = 35.8 (19.0–42.0) for placebo‐treated, and 44% prior omalizumab use. Multiple doses of barzolvolimab were well tolerated. Hair color change was the commonest adverse event in barzolvolimab‐treated patients. Across barzolvolimab doses, rapid symptom reduction within 1 week was observed and sustained during 12 weeks; 71% of patients achieved a well‐controlled (UAS7 ≤ 6) response and 57% a complete response (UAS7 = 0). Additionally, 77% of barzolvolimab‐treated patients achieved a well‐controlled response (UCT ≥ 12) and 43% a complete response (UCT = 16) by Week 12. The kinetics of disease activity paralleled tryptase suppression, indicative of MC inhibition. Patients with and without prior omalizumab treatment responded similarly.

Conclusions

This study supports barzolvolimab as a promising treatment for CSU.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chronic UrticariaProto-Oncogene Proteins c-kitAntibodies, Monoclonal, HumanizedHumansMaleFemaleAdultMiddle AgedTreatment OutcomeDouble-Blind MethodAgedYoung Adult

Stichwörter der Autor:innen

anti‐KITchronic urticariahivesmast cellmonoclonal antibodystem cell factor

Substanzen

Proto-Oncogene Proteins c-kitAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Institute of Allergology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Fraunhofer Institute for Translational Medicine and Pharmacology, Immunology and Allergology, Berlin, Germany.
  • Clinical Research Center of Alabama, AllerVie Health, University of Alabama, Birmingham, and VA Medical Center, Birmingham, Alabama, USA.
  • The Allergy Group and Treasure Valley Medical Research, Boise, Idaho, USA.
  • Celldex Therapeutics, Hampton, New Jersey, USA.
  • University of Cincinnati, Cincinnati, Ohio, USA.

ORCID-Profile: Marcus Maurer, Martin Metz, Jonathan A Bernstein

Förderung

  • Celldex Therapeutics

Zitieren

APA

Maurer, M., Metz, M., Anderson, J., Talreja, N., Young, D., Crowley, E., Heath-Chiozzi, M., Ma, R., Paradise, E., Hawthorne, T., Alvarado, D., & Bernstein, J. A. (2025). Anti‐ KIT Barzolvolimab for Chronic Spontaneous Urticaria. Allergy, 80(8), 2178-2186. https://doi.org/10.1111/all.16598

Vancouver

Maurer M, Metz M, Anderson J, Talreja N, Young D, Crowley E, et al. Anti‐ KIT Barzolvolimab for Chronic Spontaneous Urticaria. Allergy. 2025;80(8):2178-2186. doi:10.1111/all.16598

BibTeX
@article{Maurer2025,
  author = {Maurer, Marcus and Metz, Martin and Anderson, John and Talreja, Neetu and Young, Diane and Crowley, Elizabeth and Heath-Chiozzi, Margo and Ma, Rick and Paradise, Elsa and Hawthorne, Thomas and Alvarado, Diego and Bernstein, Jonathan A},
  title = {Anti‐ KIT Barzolvolimab for Chronic Spontaneous Urticaria},
  journal = {Allergy},
  year = {2025},
  volume = {80},
  number = {8},
  pages = {2178--2186},
  doi = {10.1111/all.16598}
}
Kostenlos starten →